Literature DB >> 24135280

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Qi-Wen Fan1, Christine K Cheng, W Clay Gustafson, Elizabeth Charron, Petra Zipper, Robyn A Wong, Justin Chen, Jasmine Lau, Christiane Knobbe-Thomsen, Michael Weller, Natalia Jura, Guido Reifenberger, Kevan M Shokat, William A Weiss.   

Abstract

EGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that cannot bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has been difficult because of autocrine and paracrine loops triggered by EGFRvIII alone or in heterodimers with wild-type EGFR. Here, we document coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner. We demonstrate enhancement of downstream STAT signaling triggered by EGFR-catalyzed phosphorylation of EGFRvIII, implicating EGFRvIII as a substrate for EGFR. Subsequent phosphorylation of STAT3 requires nuclear entry of EGFRvIII and formation of an EGFRvIII-STAT3 nuclear complex. Our findings clarify specific oncogenic signaling relationships between EGFR and EGFRvIII in glioblastoma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135280      PMCID: PMC3819146          DOI: 10.1016/j.ccr.2013.09.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  32 in total

1.  STAT3 tyrosine phosphorylation influences survival in glioblastoma.

Authors:  Peter Birner; Kalina Toumangelova-Uzeir; Sevdalin Natchev; Marin Guentchev
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

4.  Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.

Authors:  Jimmy A Blair; Daniel Rauh; Charles Kung; Cai-Hong Yun; Qi-Wen Fan; Haridas Rode; Chao Zhang; Michael J Eck; William A Weiss; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2007-03-04       Impact factor: 15.040

5.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

Authors:  Maria-del-Mar Inda; Rudy Bonavia; Akitake Mukasa; Yoshitaka Narita; Dinah W Y Sah; Scott Vandenberg; Cameron Brennan; Terrance G Johns; Robert Bachoo; Philipp Hadwiger; Pamela Tan; Ronald A Depinho; Webster Cavenee; Frank Furnari
Journal:  Genes Dev       Date:  2010-08-15       Impact factor: 11.361

6.  The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas.

Authors:  Mohamed Abou-Ghazal; David S Yang; Wei Qiao; Chantal Reina-Ortiz; Jun Wei; Ling-Yuan Kong; Gregory N Fuller; Nobuyoshi Hiraoka; Waldemar Priebe; Raymond Sawaya; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

7.  The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Authors:  Terrance G Johns; Rushika M Perera; Sonja C Vernes; Angela A Vitali; Diana X Cao; Webster K Cavenee; Andrew M Scott; Frank B Furnari
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

8.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation.

Authors:  Kristina W Thiel; Graham Carpenter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

9.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Authors:  Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

10.  Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Authors:  Natalia Jura; Nicholas F Endres; Kate Engel; Sebastian Deindl; Rahul Das; Meindert H Lamers; David E Wemmer; Xuewu Zhang; John Kuriyan
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

View more
  120 in total

1.  EGFRwt/vIII-PKM2-β-catenin cascade affects proliferation and chemo-sensitivity in head and neck squamous cell carcinoma.

Authors:  Chao Jing; Xin Qu; Zhaoqing Li; Chuanqiang Wu; Minghui Zhao; Yu Wang; Shanshan Sun; Shengchi Zhang; Jinliang Chen; Yu Qiao; Xiaomeng Hu; Xiaofeng Yao; Rui Jin; Xudong Wang; Lun Zhang; Xuan Zhou
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma.

Authors:  Zhenyi An; Christiane B Knobbe-Thomsen; Xiaohua Wan; Qi Wen Fan; Guido Reifenberger; William A Weiss
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

3.  In Vitro Assay to Study Tumor-macrophage Interaction.

Authors:  Zhenyi An; William A Weiss
Journal:  J Vis Exp       Date:  2019-08-01       Impact factor: 1.355

4.  Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

Authors:  Gao Guo; Ke Gong; Vineshkumar Thidil Puliyappadamba; Nishah Panchani; Edward Pan; Bipasha Mukherjee; Ziba Damanwalla; Sabrina Bharia; Kimmo J Hatanpaa; David E Gerber; Bruce E Mickey; Toral R Patel; Jann N Sarkaria; Dawen Zhao; Sandeep Burma; Amyn A Habib
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

5.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

Review 6.  NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

Authors:  G Kenneth Gray; Braden C McFarland; Susan E Nozell; Etty N Benveniste
Journal:  Expert Rev Neurother       Date:  2014-09-29       Impact factor: 4.618

7.  EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Authors:  Alison Roos; Harshil D Dhruv; Sen Peng; Landon J Inge; Serdar Tuncali; Michael Pineda; Nghia Millard; Zachary Mayo; Jennifer M Eschbacher; Joseph C Loftus; Jeffrey A Winkles; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2018-05-03       Impact factor: 5.852

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.

Authors:  Daniel R Premkumar; Esther P Jane; Ian F Pollack
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 10.  Ligand-Independent EGFR Signaling.

Authors:  Gao Guo; Ke Gong; Bryan Wohlfeld; Kimmo J Hatanpaa; Dawen Zhao; Amyn A Habib
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.